

Kevork Minas Peltekian

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6969942/kevork-minas-peltekian-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

5,946
citations

32
h-index

77
g-index

86
ext. papers

6,651
ext. citations

5.7
avg. IF

4.54
L-index

#	Paper	IF	Citations
76	HBV coinfection and in-hospital outcomes for COVID-19: a systematic review and meta-analysis. <i>Canadian Liver Journal</i> , 2021 , 4, 16-22	0.3	1
75	Canadian liver transplant allocation for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019 , 71, 1058-1060	19.4	3
74	Epidemiology and liver transplantation burden of primary biliary cholangitis: a retrospective cohort study. <i>CMAJ Open</i> , 2018 , 6, E664-E670	2.5	7
73	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 161-176	18.8	1196
72	Blue-Print for Elimination of Hepatitis C Viral Infection: One Step Closer. <i>Annals of Hepatology</i> , 2017 , 16, 696-698	3.1	1
71	Real-world effectiveness of peginterferon $\alpha 2b$ plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWER and RediPEN studies. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016 , 35, 597-609	5.3	0
70	Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience. <i>Transplantation</i> , 2016 , 100, 1059-65	1.8	32
69	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , 2014 , 21 Suppl 1, 34-59	3.4	271
68	Historical epidemiology of hepatitis C virus (HCV) in selected countries. <i>Journal of Viral Hepatitis</i> , 2014 , 21 Suppl 1, 5-33	3.4	182
67	Burden of disease and cost of chronic hepatitis C infection in Canada. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014 , 28, 243-50	2.8	110
66	Strategies to manage hepatitis C virus (HCV) disease burden. <i>Journal of Viral Hepatitis</i> , 2014 , 21 Suppl 1, 60-89	3.4	140
65	Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. <i>World Journal of Gastroenterology</i> , 2012 , 18, 767-77	5.6	51
64	Is pre-treatment liver biopsy necessary for all hepatitis C genotypes?. <i>Annals of Hepatology</i> , 2011 , 10, 260-269	3.1	0
63	Coping strategies used by patients infected with hepatitis C virus who are facing medication costs. <i>Canadian Journal of Hospital Pharmacy</i> , 2011 , 64, 131-40	0.5	5
62	Simultaneous liver kidney transplantation: a medical decision analysis. <i>Transplantation</i> , 2011 , 91, 121-7	1.8	31
61	Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV coinfection. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 170-80	3.4	8
60	Comparison of cancer care for hepatocellular carcinoma at two tertiary-care referral centers from high and low endemic regions for viral hepatitis. <i>Journal of Gastrointestinal Cancer</i> , 2011 , 42, 228-35	1.6	5

59	Diabetes mellitus: risk factor for advanced liver disease. <i>Cmaj</i> , 2011 , 183, 586	3.5	
58	Canada needs viral hepatitis action plan. <i>Cmaj</i> , 2011 , 183, 1751	3.5	
57	Is pre-treatment liver biopsy necessary for all hepatitis C genotypes?. <i>Annals of Hepatology</i> , 2011 , 10, 260-9	3.1	
56	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010 , 42, 658-60	36.3	337
55	Identifying HCV genotype 1 patients at risk of relapse. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 546-51	2.2	4
54	The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. <i>Transfusion Medicine Reviews</i> , 2010 , 24 Suppl 1, S7-S27	7.4	78
53	Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. <i>Journal of the American College of Surgeons</i> , 2009 , 208, 134-47	4.4	173
52	Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. <i>Liver Transplantation</i> , 2009 , 15, 504-8	4.5	46
51	The 1F7 idiotype is selectively expressed on CD5+ B cells and elevated in chronic hepatitis C virus infection. <i>Immunology and Cell Biology</i> , 2009 , 87, 457-63	5	6
50	Hepatic artery aneurysm associated with prune belly syndrome: a case report and review of the literature. <i>Journal of Surgical Education</i> , 2009 , 66, 43-7	3.4	10
49	Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. <i>New England Journal of Medicine</i> , 2009 , 360, 2544-55	59.2	494
48	Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. <i>Gastroenterology</i> , 2009 , 136, 1618-28.e2	13.3	197
47	Future directions for investigation of fatigue in chronic hepatitis C viral infection. <i>Chronic Illness</i> , 2009 , 5, 115-28	1.4	13
46	Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 43-50	6.1	26
45	Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals. <i>BMC Immunology</i> , 2008 , 9, 28	3.7	17
44	Type II gall bladder perforation with abdominal wall abscess in a cirrhotic patient: case report and review of the literature. <i>Journal of Surgical Education</i> , 2008 , 65, 367-71	3.4	14
43	Effect of interferon-alpha, ribavirin, pentoxifylline, and interleukin-18 antibody on hepatitis C sera-stimulated hepatic stellate cell proliferation. <i>Journal of Interferon and Cytokine Research</i> , 2008 , 28, 643-51	3.5	15
42	Survival after liver transplantation for hepatitis C is unchanged over two decades in Canada. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008 , 22, 153-4		3

41	Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 52-7	3.4	25
40	Early invasive <i>Listeria monocytogenes</i> infection after orthotopic liver transplantation: case report and review of the literature. <i>Liver Transplantation</i> , 2008 , 14, 88-91	4.5	13
39	Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2181-8	0.7	81
38	Complementary and alternative medicine use by patients chronically infected with hepatitis C virus. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007 , 21, 589-95		24
37	Induction versus noninduction antiviral therapy for chronic hepatitis C virus in patients with congenital coagulation disorders: a Canadian multicentre trial. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007 , 21, 91-5		1
36	Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. <i>Liver Transplantation</i> , 2007 , 13, 1109-14	4.5	237
35	Chylous ascites secondary to pancreatitis: management of an uncommon entity using parenteral nutrition and octreotide. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 2261-4	4	25
34	An evidence-based manual for abdominal paracentesis. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 3307-14		46
33	[615] MANAGEMENT OF CHRONIC HEPATITIS C IN A DIVERSE POPULATION WITH PEGINTERFERON α -2a AND RIBAVIRIN: FINAL RESULTS OF THE CANADIAN PEGASYS EXPANDED ACCESS PROGRAM (EAP). <i>Journal of Hepatology</i> , 2007 , 46, S232-S233	13.4	2
32	12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. <i>Liver Transplantation</i> , 2006 , 12, 1464-72	4.5	83
31	Acute liver failure induced by green tea extracts: case report and review of the literature. <i>Liver Transplantation</i> , 2006 , 12, 1892-5	4.5	117
30	Colon cancer screening. <i>Cmaj</i> , 2006 , 174, 975; author reply 975-6	3.5	2
29	Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. <i>Gut</i> , 2006 , 55, 1631-8	19.2	67
28	Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 397-408	6.1	74
27	Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction: are the equations for estimating renal function better?. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2006 , 20, 521-6		50
26	Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2006 , 20, 725-34		4
25	Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant. <i>Transplantation</i> , 2006 , 82, 494-500	1.8	35
24	Poor prediction of the glomerular filtration rate using current formulas in de novo liver transplant patients. <i>Transplantation</i> , 2006 , 82, 433-6	1.8	14

23	Choroidal neovascularization with interferon associated retinopathy: case report and review of literature. <i>Annals of Hepatology</i> , 2006 , 5, 172-6	3.1	
22	Review article: the changing epidemiology of hepatocellular carcinoma in Canada. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22, 17-22	6.1	35
21	A Canadian multicenter retrospective study evaluating transjugular liver biopsy in patients with congenital bleeding disorders and hepatitis C: is it safe and useful?. <i>American Journal of Hematology</i> , 2005 , 78, 85-93	7.1	44
20	Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. <i>Liver Transplantation</i> , 2005 , 11, 1064-72	4.5	116
19	Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. <i>Liver Transplantation</i> , 2005 , 11, 1412-6	4.5	108
18	Canadian mortality rates for liver disease: taking a closer look at ICD coding. <i>Canadian Journal of Public Health</i> , 2004 , 95, 198-200	3.2	6
17	Finally...real utility scores for hepatitis C patients!. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2004 , 18, 411-2		1
16	Protective anti-donor IgM production after crossmatch positive liver-kidney transplantation. <i>Liver Transplantation</i> , 2004 , 10, 315-9	4.5	18
15	Immunoglobulin-G subclass antidonor reactivity in transplant recipients. <i>Liver Transplantation</i> , 2004 , 10, 1055-9	4.5	27
14	Utility of MELD and Child-Turcotte-Pugh scores and the Canadian waitlisting algorithm in predicting short-term survival after liver transplant. <i>Clinical and Investigative Medicine</i> , 2004 , 27, 162-7	0.9	6
13	Fatigue and Quality of Life in Hepatitis C: Fact or Fiction?. <i>Journal of Clinical Psychology in Medical Settings</i> , 2003 , 10, 267-271	2	3
12	Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. <i>Liver Transplantation</i> , 2003 , 9, 587-95	4.5	46
11	A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 346-50	3.2	78
10	Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. <i>Liver Transplantation</i> , 2001 , 7, 701-8	4.5	124
9	De novo use of low-dose tacrolimus and sirolimus in liver transplantation. <i>Transplantation Proceedings</i> , 2001 , 33, 1341	1.1	11
8	Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. <i>Hepatology</i> , 2000 , 31, 207-10	11.2	363
7	Sirolimus-tacrolimus combination immunosuppression. <i>Lancet, The</i> , 2000 , 355, 376-7	4.0	282
6	Cost of liver transplantation using tacrolimus. <i>Transplantation Proceedings</i> , 1998 , 30, 1502	1.1	4

- 5 Prostaglandins in liver failure and transplantation: regeneration, immunomodulation, and cytoprotection. Prostaglandins in Liver Transplantation Research Group. *Liver Transplantation*, **1996**, 2, 171-84 12
- 4 Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. *Hepatology*, **1995**, 22, 432-438 11.2 255
- 3 Detection of Crohn's ileitis by endovaginal ultrasonography. *Abdominal Imaging*, **1994**, 19, 400-2 6
- 2 Gut Toxicity of 5-ASA?. *Canadian Journal of Gastroenterology & Hepatology*, **1993**, 7, 170-172
- 1 Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy. *Canadian Journal of Gastroenterology & Hepatology*, **1988**, 2, 5-11 18